TY - JOUR
T1 - Atopic dermatitis
T2 - Addressing allergy, infection, itch and complementary therapies
AU - Ahluwalia, Jusleen
AU - Davis, Dawn Marie
AU - Jacob, Sharon
AU - Waldman, Andrea
AU - Ong, Peter Y.
AU - Cohen, Stuart
AU - Friedman, Adam
AU - Lio, Peter
AU - Jetter, Nathan
AU - Bienstock, Jeffrey
AU - LeBovidge, Jennifer
AU - Spergel, Jonathan
AU - Fonacier, Luz
N1 - Funding Information:
1Division of Pediatric and Adolescent Dermatology, Rady Children’s Hospital, San Diego, California. 2Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine, La Jolla, California. 3Department of Dermatology, Mayo Clinic Rochester, Rochester, Minnesota. 4Department of Dermatology, Loma Linda University Medical Center, Loma Linda, California. 5Department of Allergy & Immunology, University of Southern California, Los Angeles. 6Department of Pediatrics, University of California, San Diego. 7Department of Dermatology, George Washington School of Medicine and Health Sciences 8Departments of Dermatology and Pediatrics, Northwestern University Fein-berg School of Medicine, Chicago Integrative Eczema Center 9Patient Advocate, The National Eczema Association, San Rafael, California. 10PediatriCare Associates, Fairlawn, New Jersey. 11Allergy Program, Division of Immunology, Boston Children’s Hospital 12Division of Allergy and Immunology, Children’s Hospital of Pennsylvania, Philadelphia, Pennsylvania. 13Department of Medicine, State University of New York at Stony Brook, NY; Allergy & Immunology Training Program, Winthrop University Hospital, Mineola, New York. Disclosures: Drs Ahluwalia, Davis, Jacob, Waldman, Ong, Cohen, Jetter, Bienstock, LeBovidge, and Spregel have no conflicts of interest or financial disclosures. Dr Friedman’s relevant conflicts: Consultant for Encore, Exeltis, and Pfizer; Speaker for Regeneron and Pfizer. Dr Lio has received grant funding and has been a PI for AO Biome topical probiotic spray; he has received grant funding from La Fondation pour le Dermatite Atopique for acupressure research; he is a consultant and speaker for Pfizer and Regeneron. He is a consultant for Johnson and Johnson, Theraplex, Galderma, and Valeant. Dr Fonacier has received research/educational grants made to Winthrop University Hospital from Genentech, Baxter; and has received honoraria and is a consultant for Regeneron. Correspondence: Luz Fonacier, MD; LFonacier@nyuwinthrop.org
Publisher Copyright:
© 2017 Frontline Medical Communications.
PY - 2017/9/1
Y1 - 2017/9/1
N2 - Atopic dermatitis (AD) is a complex condition that results from the dynamic interplay between genetic predisposition, skin barrier defects, environmental factors, and a dysfunctional immune system. As a result, AD can be complicated by irritant and allergic contact dermatitis and imbalances in the skin microbiome, which can subsequently exacerbate the severity and complicate the course of preexisting atopic disease. Itch is an important symptom of AD, as it plays a large role in the quality of life of patients and their families. Since AD is a chronic, inflammatory disease that recrudesces throughout life, many have utilized alternative and/or complementary therapies, as monotherapy or in conjunction with conventional therapies, as a form of management.
AB - Atopic dermatitis (AD) is a complex condition that results from the dynamic interplay between genetic predisposition, skin barrier defects, environmental factors, and a dysfunctional immune system. As a result, AD can be complicated by irritant and allergic contact dermatitis and imbalances in the skin microbiome, which can subsequently exacerbate the severity and complicate the course of preexisting atopic disease. Itch is an important symptom of AD, as it plays a large role in the quality of life of patients and their families. Since AD is a chronic, inflammatory disease that recrudesces throughout life, many have utilized alternative and/or complementary therapies, as monotherapy or in conjunction with conventional therapies, as a form of management.
UR - http://www.scopus.com/inward/record.url?scp=85048230455&partnerID=8YFLogxK
U2 - 10.12788/j.sder.2017.038
DO - 10.12788/j.sder.2017.038
M3 - Article
AN - SCOPUS:85048230455
SN - 1085-5629
VL - 36
SP - 112
EP - 117
JO - Seminars in Cutaneous Medicine and Surgery
JF - Seminars in Cutaneous Medicine and Surgery
IS - 3
ER -